TT-232: An anti-tumour and anti-inflammatory peptide therapeutic in clinical development

György Kéri, Richard Schwab, Orsolya Szokolóczi, Tamás Szüts, János Szolcsányi

Research output: Contribution to journalArticle

1 Citation (Scopus)


TT-232 is a structural derivative of the peptide hormone somatostatin with selective anti-proliferative and anti-inflammatory properties. It has a strong anti-tumour activity both in vitro and in vivo on a wide range of tumour models and induces apoptosis. Its anti-tumour activity is mediated through the SSTR1 receptor and by the tumour specific isoform of pyruvate kinase. TT-232 has been shown to be a potent neurogenic inflammation inhibitory, anti-inflammatory and analgesic agent with a broader spectrum than presently available anti-inflammatory/analgesic drugs. In animal models it is effective against neurogenic inflammation and blocks neuropathic hyperalgesia where COX-1 or COX-2 inhibitors (e.g. diclofenac or meloxicam) proved ineffective. TT-232 has passed phase I clinical trials without toxicity and significant side effects. Human phase II efficacy studies are ongoing in melanoma indication. Two more oncological indications and phase II clinical trials in inflammatory diseases, including rheumatoid arthritis and burn injuries are in preparation. This compound has the perspective to become the first drug in molecularly targeted therapy of inflammation where a combined effect of anti-inflammatory, analgesic and neurogenic inflammation inhibiting activity can be achieved.

Original languageEnglish
Pages (from-to)3-15
Number of pages13
JournalInternational Journal of Peptide Research and Therapeutics
Issue number1
Publication statusPublished - Mar 1 2005


  • Analgesic activity
  • Anti-inflammatory activity
  • Anti-tumour activity
  • Clinical development
  • Neurogenic inflammation
  • Somatostatin analogue
  • TT-232

ASJC Scopus subject areas

  • Analytical Chemistry
  • Bioengineering
  • Biochemistry
  • Molecular Medicine
  • Drug Discovery

Fingerprint Dive into the research topics of 'TT-232: An anti-tumour and anti-inflammatory peptide therapeutic in clinical development'. Together they form a unique fingerprint.

  • Cite this